KR20160056268A - Composition for the inhibition of UV-induced melanogenesis or anti inflammatory comprising extracts or fractions of Psidium guajava L. - Google Patents
Composition for the inhibition of UV-induced melanogenesis or anti inflammatory comprising extracts or fractions of Psidium guajava L. Download PDFInfo
- Publication number
- KR20160056268A KR20160056268A KR1020150139525A KR20150139525A KR20160056268A KR 20160056268 A KR20160056268 A KR 20160056268A KR 1020150139525 A KR1020150139525 A KR 1020150139525A KR 20150139525 A KR20150139525 A KR 20150139525A KR 20160056268 A KR20160056268 A KR 20160056268A
- Authority
- KR
- South Korea
- Prior art keywords
- guava
- composition
- fraction
- present
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000000284 extract Substances 0.000 title claims abstract description 41
- 244000236580 Psidium pyriferum Species 0.000 title claims abstract description 6
- 235000013929 Psidium pyriferum Nutrition 0.000 title claims abstract description 6
- 230000005764 inhibitory process Effects 0.000 title claims description 12
- 230000003061 melanogenesis Effects 0.000 title claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 4
- 241000508269 Psidium Species 0.000 claims abstract description 63
- 230000000694 effects Effects 0.000 claims abstract description 31
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 16
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 16
- 230000037361 pathway Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000002034 butanolic fraction Substances 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 5
- 239000002044 hexane fraction Substances 0.000 claims description 5
- 239000002037 dichloromethane fraction Substances 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 229940008523 psidium guajava extract Drugs 0.000 claims description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Natural products O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 33
- 230000002401 inhibitory effect Effects 0.000 abstract description 24
- 101150060735 orai1 gene Proteins 0.000 abstract description 24
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 16
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 16
- 102000004310 Ion Channels Human genes 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 230000002087 whitening effect Effects 0.000 abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 3
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 208000026278 immune system disease Diseases 0.000 abstract description 3
- 230000002757 inflammatory effect Effects 0.000 abstract description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 2
- 231100000433 cytotoxic Toxicity 0.000 abstract description 2
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 108090000862 Ion Channels Proteins 0.000 description 12
- -1 tracant Substances 0.000 description 11
- 239000006071 cream Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009460 calcium influx Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004378 Melanocortin Receptors Human genes 0.000 description 3
- 108090000950 Melanocortin Receptors Proteins 0.000 description 3
- 108010008364 Melanocortins Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000297627 Senna alata Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002865 melanocortin Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000012402 patch clamp technique Methods 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101100043696 Drosophila melanogaster Stim gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000745520 Homo sapiens Calcium release-activated calcium channel protein 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000049666 ORAI1 Human genes 0.000 description 1
- 108700027851 ORAI1 Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000276216 Persicaria viscofera Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 102000050732 human ORAI1 Human genes 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000018105 immunodeficiency 10 Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003592 new natural product Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
The present invention relates to a skin whitening or anti-inflammatory composition containing guava, more particularly an extract of Guidaba leaf (Psidium guajava L.) or a fraction thereof.
When the composition of the present invention is used, it has an effect of inhibiting tyrosinase activity as well as inhibiting Orai-1 ion channel which plays an important role in skin darkening due to skin melanin cell melanin formation during sunlight irradiation. In addition, Orai-1 is a calcium ion pathway important for immunological activity, and effectively inhibiting it can solve various inflammatory diseases.
Since guava leaves are safe substances that are not cytotoxic enough to be used for edible purposes, they may be useful for the prevention and treatment of inflammatory / immune diseases such as bronchial asthma, allergic rhinitis and atopic dermatitis.
Description
The present invention relates to a polygonum viscoferum ) extract or a fraction thereof as an active ingredient for skin whitening or anti-inflammation.
Melanogenesis due to the activity of melanocytes can occur through two signal transduction mechanisms. The first is the mechanism of melanin formation by intracellular cAMP stimulation and the second is the mechanism of melanin formation by increasing intracellular calcium concentration.
In the case of melanocortin-induced melanocortin-induced melanocortin (POMC) / melanocortin receptors (melanocortin receptors), melanocortin receptors 1 (MC1-R) / cyclicAMP (cAMP) pathway, initiated by melanocyte-stimulating hormone (α-MSH) or adrenocorticotropic hormone (ACTH).
On the other hand, according to JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012 May; 132 (5): 1443-51), the first journal in the ISI web of knowledge dermatology, the ultraviolet When examined, melanin cells are activated to form melanin, which is believed to be due to an increase in intracellular calcium concentration. More specifically, the
In the above-mentioned article, it was confirmed that the treatment of Orai-1 inhibitor using human melanocytes inhibited the formation of melanin due to ultraviolet light. Therefore, if a drug capable of inhibiting the melanocyte Orai-1 ion channel is developed, it is expected that an inhibitor of skin blackening by ultraviolet rays can be developed.
Recently, much attention has been focused on functional cosmetics having functions of antioxidation, wrinkle reduction, whitening, etc., obtained from natural extracts in order to reduce skin irritation caused by various chemical substances and the like. In addition to low adverse effects on the skin, natural materials have recently become increasingly appreciated as a raw material for skin external preparations, as consumers' responses to external preparations using natural materials have increased.
The active ingredients used for suppression of photoaging are not available as cosmetic raw materials, are very unstable, are not easily transferred to the skin, require a special stabilization system and delivery system, and the effect of improving skin wrinkles is not visible Recently, retinoids have been increasingly attracted attention as a skin protective agent containing retinoids. Currently, retinoids are a means for solving photoaging phenomena such as wrinkles, skin thickening, sagging, and elasticity reduction which are accumulated as sunlight . However, retinoids are very unstable compounds, and they are sensitive to ultraviolet rays, moisture, heat, and oxygen, causing chemical changes easily.
On the other hand, when the immune cells are exposed to the antigen and the antibody, the immunoreceptor stimulation occurs and the continuous calcium influx is activated by the calcium glass and ER calcium depletion due to intracellular phospholipase C (PLC) activity. The influx of calcium into the immune cells is accomplished through the ORAI-1 & STIM protein complex whose molecular properties are revealed in 2006. Calcium influx through this complex is known to be important in activating the calcineurin-NFAT-IL-2 production pathway. Without calcium influx through the ORAI1 ion channel, IL-2 production is reduced, lymphocyte proliferation and T cell-mediated immune responses are reduced, resulting in immunodeficiency disease. Indeed, a serious immunodeficiency disease can occur in humans when the ORAI-1 ion channel and STIM1 deficiency are reported in Nature and the New England Journal of Medicine.
The activity of calcineurin or mRNA transcriptional regulatory factors, which are the targets of drugs such as tacrolimus and glucocorticoid, which are currently clinically applied as powerful immunosuppressants, is initiated by an increase in intracellular calcium concentration, It is regulated by the Orai-STIM complex, which carries calcium directly into the cell. Therefore, if a substance that regulates these ion channels is developed and used, it can have a strong immunoregulatory effect.
Therefore, if a natural substance-derived inflammation inhibitor is developed targeting the Orai-1 ion channel that produces an intracellular calcium signal, it will be able to exert a much stronger immunosuppressive ability than the existing therapeutic agent.
On the other hand, guava is an American tropical plant of the genus Psidium (Myrtaceae). It is a medicinal plant that can utilize leaves, bark and fruit as well as potted plants for healthful and medicinal purposes. Guava, especially guava leaves contain many vitamins and minerals such as vitamin C, magnesium, potassium, and calcium. It is also known to contain many kinds of vitamins and minerals, including peroxidation-inhibiting action (cancer prevention) Polyphenol component) have been reported.
The present inventors not only inhibited skin blackening through inhibition of melanin formation due to exposure to ultraviolet rays, but also studied melanin inhibitory effects and induction of various inflammatory diseases in Guava extract or its fractions while studying natural products effective for inflammatory diseases The present invention has been accomplished on the basis of this finding.
It is therefore an object of the present invention to provide a skin whitening or antiinflammatory composition comprising guava extract or a fraction thereof.
However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
In order to achieve the object of the present invention as described above, the present invention provides a guava (Psidium guajava extract or a fraction thereof as an active ingredient.
In one embodiment of the present invention, the guava may be a guava leaf (Psidium guajava L.).
In another embodiment of the present invention, the extract may be obtained by extracting guava with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
In another embodiment of the present invention, the alcohol having 1 to 4 carbon atoms may be methanol or ethanol.
In another embodiment of the present invention, the fraction may be a hexane fraction, a dichloromethane fraction, an ethyl acetate fraction or a butanol fraction obtained by sequentially fractionating a guava extract with hexane, dichloromethane, ethyl acetate or butanol.
In another embodiment of the present invention, the composition can inhibit melanin formation through inhibition of the ORAI-1 ion channel.
In another embodiment of the present invention, the composition may inhibit tyrosinase activity.
In another embodiment of the present invention, the composition can inhibit skin blackening due to ultraviolet exposure.
In another embodiment of the present invention, the composition may be a pharmaceutical composition.
In another embodiment of the present invention, the composition may be a cosmetic composition.
In another embodiment of the present invention, the composition may be a functional food composition.
The present invention relates to a method for the treatment of psoriasis guajava extract or a fraction thereof as an active ingredient.
In one embodiment of the invention, the immunosuppression may be through inhibition of the ORAI-I pathway.
When the composition of the present invention is used, it has an effect of inhibiting tyrosinase activity as well as inhibiting Orai-1 ion channel which plays an important role in skin darkening due to skin melanin cell melanin formation during sunlight irradiation. In addition, Orai-1 is a calcium ion pathway important for immunological activity, and thus it is effective to solve various inflammatory diseases by effectively inhibiting it.
Since guava leaves are safe substances that are not cytotoxic enough to be used for edible purposes, they may be useful for the prevention and treatment of inflammatory / immune diseases such as bronchial asthma, allergic rhinitis and atopic dermatitis.
1 is a graph showing the inhibitory effect of ORAI-1 on the butanol fraction of guava fraction.
Figure 2 shows the results of calculating the ORAI-1 ion channel inhibition rate of guava extract and its fractions.
Fig. 3 is a graph showing the inhibitory effect of guava extract and its fractions on tyrosinase activity.
FIG. 4 shows the results of confirming the effect of the butanol fraction of guava fraction on the treatment of atopic dermatitis by sensory evaluation in an atopic dermatitis animal model.
The inventors of the present invention have found that guava extract and its fractions have an effect of inhibiting ORAI-1 activity while engaging in research to find a new natural product having an effect of inhibiting melanin formation on various natural products, .
Hereinafter, the present invention will be described in detail.
The present invention relates to a method for the treatment of psoriasis guajava extract or a fraction thereof as an active ingredient. At this time, guava preferably uses guava leaves.
In the present invention, guava extract can be extracted using conventional solvents known in the art for extracting the extract from natural products, that is, under ordinary temperature and pressure conditions, using a conventional solvent. For example, in the present invention, the guava extract may be at least one solvent selected from water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof, preferably methanol or ethanol. In addition, the method for extracting the extract from guava may be carried out by various methods such as hot water extraction, cold extraction, reflux extraction, and ultrasonic extraction, but is not limited thereto.
In the present invention, the guava fraction is obtained by extracting guava with a solvent, filtering the extracted extract, concentrating under reduced pressure to obtain a guava extract, and sequentially fractionating it using hexane, dichloromethane, ethyl acetate and butanol Can be. Preferably a butanol fraction.
In one embodiment of the present invention, guava extract and its fractions were prepared (see Example 1), and their ORAI-1 inhibitory effect was confirmed. As a result, the guava extract or its fractions according to the present invention showed an ORAI- (See Example 2). ≪ tb > < TABLE >
In another embodiment of the present invention, it was confirmed that guava extract or its fractions had an inhibitory effect on tyrosinase activity, and the guava extract or its fractions according to the present invention had a superior tyrosinase activity inhibitory effect as compared with the control group (see Example 3) ).
Therefore, the guava extract or the fractions thereof according to the present invention have an effect of inhibiting melanin formation due to exposure to ultraviolet rays through inhibition of ORAI-1 ion channel and inhibition of tyrosinase activity, And can be usefully used for applications.
Accordingly, the composition for whitening skin of the present invention may be in the form of a pharmaceutical composition, and the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier containing guava extract or its fractions as an active ingredient. Pharmaceutically acceptable carriers in the pharmaceutical compositions of the present invention include, but are not limited to, saline, buffered saline, water, glycerol, and ethanol.
The pharmaceutical composition of the present invention can be prepared into any formulation for oral or parenteral administration, and preferably has an external preparation for skin. The dermatological formulations can be, but are not limited to, powders, gels, ointments, creams, liquids or aerosol formulations.
The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, skin application, intravenous injection, subcutaneous injection, intraperitoneal injection or topical application) depending on the intended method, The severity of the disease, the form of the drug, the route of administration, and the time, but may be suitably selected by those skilled in the art.
The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dosage level is determined depending on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, body weight, absorbency of the active ingredient, inactivity and excretion rate, disease type, May be administered at a daily dose of 0.001 to 150 mg, preferably 0.01 to 100 mg, per 1 kg of body weight, or one to three divided doses per day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.
In addition, the skin whitening composition of the present invention may be in the form of a cosmetic composition, and the cosmetic composition may contain guava extract or a fraction thereof as an active ingredient.
The cosmetic composition of the present invention may be prepared into any of the formulations conventionally produced in the art, and may be prepared, for example, as a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, But are not limited to, cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
The cosmetically effective carrier contained in the cosmetic composition of the present invention may be a carrier conventionally used in the art depending on the formulation. When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters.
The ingredients included in the cosmetic composition of the present invention include, in addition to the active ingredient and the carrier ingredient, the ingredients conventionally used in cosmetic compositions and include conventional ingredients such as antioxidants, stabilizers, solubilizers, vitamins, May include adjuvants.
Furthermore, the skin whitening composition of the present invention may be in the form of a functional food composition for preventing or improving whitening, and the functional food composition may contain guava extract or its fractions as an active ingredient.
There is no particular limitation on the kind of the food. Examples of foods to which the active ingredient can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolates, snacks, confectionery, pizza, ramen noodles, other noodles, gums, ice cream, , Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense.
In the functional food composition of the present invention, the active ingredient may be directly added to the food or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). In general, the composition of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material, in the production of food or beverage. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range.
The functional food composition of the present invention is not particularly limited to the ingredients other than those containing the active ingredient as the essential ingredient in the indicated ratio and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary drinks . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above . The ratio of the above-mentioned natural carbohydrate can be appropriately determined by a person skilled in the art.
In addition to the above, the functional food composition of the present invention may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, And salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. These components may be used independently or in combination. The ratios of these additives can also be appropriately selected by those skilled in the art.
In addition, the guava extract or its fractions according to the present invention have an immunosuppressive effect through inhibition of ORAI-1 ion channel, and can be used for prevention of skin damage due to ultraviolet rays, prevention of inflammatory / immune diseases such as bronchial asthma, allergic rhinitis, And may be useful for improvement and treatment.
In another embodiment of the present invention, the therapeutic effect of the guava butanol fraction in the atopic dermatitis animal model has been confirmed to show a far superior therapeutic effect than the 1% hydrocortisone ointment currently used most effectively and effectively for the treatment of atopic dermatitis See Example 4).
Accordingly, the present invention relates to a method for producing guajava extract or a fraction thereof as an active ingredient. The anti-inflammatory or immunosuppressive composition of the present invention can also be used in the form of pharmaceutical, cosmetic, or functional food composition, which is the same as described above, and thus a detailed description thereof will be omitted.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.
[Example]
Example 1. Preparation of guava extract and fractions
The guava leaves (Psidium guajava L.) were cut three times, and then 3 L of 70% MeOH was heated and extracted twice for 3 hours, and the solvent and water were evaporated by filtration to prepare powdered guava extract. Thereafter, water is added to the Guava leaf MeOH extract powder, hexane is added thereto, and the mixture is shaken to separate the organic solvent layer and the water layer. The dichloromethane (CH 2 Cl 2 ) is again added to the water layer, Layer and the water layer are separated from each other and ethyl acetate (EtOAc) is added again to the water layer to separate the organic solvent layer and the water layer from each other, and then the butanol (BuOH) is again added to the water layer to separate the organic solvent layer and the water layer The respective hexane fractions, dichloromethane fractions, ethyl acetate fractions and butanol fractions were recovered.
Example 2. Confirmation of ORAI-1 Inhibitory Effect of Guava Fractions
The ORAI-1 inhibitory effect of the guava methanol extract, hexane fraction, dichloromethane fraction, ethyl acetate fraction and butanol fraction prepared in Example 1 was measured. The human ORAI-1 protein expressed in the immune cells was overexpressed in the HEK-293T cell line to measure the intracellular calcium current in real time using a patch clamp technique Respectively.
The patch clamp technique for Orai-1 overexpressed HEK-293T cell line was performed by whole cell patch clamp. Glass electrodes with resistances of 2 to 4 Mohm were used. Signals from a patch clamp amplifier (Axopatch 700B, Axon instruments, USA) were observed through Axoscope 10.4 and Clampfit 10.4 (cAxon instruments, USA). (Digidata-1440A, Axon instruments, USA) equipped with a pClamp software (v10.4) and a personal computer with an operating clock of 3.2GHz to record and store the current response at a fixed voltage and excitation voltage, Respectively. The results obtained for the membrane voltage clamp were analyzed and processed using clampfit v10.4, origin (Microcal software, USA).
To measure the current through Orai-1, the extracellular solution was pH 7.4 solution containing 135 mM NaCl, 3.6 mM KCl, 1 mM MgCl 2 , 10 mM CaCl 2 , 5 mM D-glucose, and 10 mM HEPES And the pipette solution used was a solution of pH 7.2 containing 130 mM Cs-Glutamate, 20 mM BAPTA, 1 mM MgCl 2 , 3 mM MgATP, 0.002 mM sodium pyruvate and 20 mM HEPES. To activate the Orai-1 ion channel, 20 μM inositol triphosphate (InsP 3 ) was added to the pipet solution.
As a result, as shown in Figs. 1 and 2, it was confirmed that the guava extract or its fractions had an inhibitory effect on the ORAI-1 ion channel, and the guava butanol fraction had an excellent effect for inhibiting ORAI-1 activity .
Example 3. Confirmation of tyrosinase activity inhibitory effect of guava extract and fractions
In order to measure the inhibition effect of the guava methanol extract, hexane fraction, dichloromethane (methylene chloride) fraction, ethyl acetate fraction and butanol fraction produced through Example 1, tyrosinase inhibition was tested as follows.
Tyrosinase is an enzyme that plays an important role in the formation of melanin from L-DOPA. It treats L-DOPA, a substrate, with tyrosinase and guava extract and fractions to induce melanin formation by tyrosinase. Experiments were carried out to see how much it was suppressed compared to before treatment. More specifically, a mixture of sodium phosphate buffer (pH 6.8, 1/15 M; 1.2 mL), Levodopa (L-DOPA) (1.5 mM; 0.5 mL) and guava extract and fractions (10 mg / The sample was placed in a solution containing tyrosinase and reacted at 30 ° C for 10 minutes. When the reaction occurred and melanin was formed, the absorbance was measured at 475 nm using a microplate reader. As a control, 200 μg / mL of kojic acid was used.
As a result, as shown in FIG. 3, it was confirmed that Guava extract or its fractions had an inhibitory effect on tyrosinase activity as compared with the control group. In particular, it was confirmed that guava butanol fraction had an excellent effect for inhibiting tyrosinase activity.
Example 4. Confirmatory effect of atopic dermatitis treatment using animal model
The therapeutic effect of the guava butanol fraction prepared in Example 1 was observed in an animal model of atopic dermatitis.
The NC / Nga mice used in this experiment is an ointment that contains the house dust mite allergen in spontaneous atopic dermatitis is well known, but a mortar model with low spontaneous dermatitis induction rate, the severe differences in the intensity of the induced atopic dermatitis experiments (AD ointment ® , Biostir) to induce atopic dermatitis for 2 weeks and then treated with guava butanol extract for 1 week. The modified SCORAD score was used to evaluate the treatment effect of atopic dermatitis.
4-1. Preparation of reagents and experimental animals
To evaluate the therapeutic effect, 1% hydrocortisone lotion (lactic care lotion, GlaxoSmithKline) and glycerin (Ninjin Pharma) were prepared. The test sample was prepared by dissolving 1% of guava butanol fraction in glycerin. ® Biostir's AD ointment for atopic dermatitis induction, 4% SDS (Sodium dodecyl sulfate ), hair removal cream was prepared (Veet ®, oxy kitben kijyeo below).
Experimental animals were fed with 4-week-old female NC / Nga mice (SLC Japan, Shizuoka, Japan) and fed with solid feed and water freely. They were kept at room temperature 22 ± 2 ℃, %, Illuminance 200 lux (8 hours lighting, 20 hours off), and adapted to the laboratory environment for 1 week in SPF environment.
4-2. Induction of atopic dermatitis
After anesthesia, the NC / Nga mice after complete removal of hair after hair removal cream a hair removal up to the top, such as electric epilator from ear to fully dry with a hair dryer applied to the hair removal portion the AD ointment ® 100mg using a flat stick Respectively. From 2 times of application, 150 ㎕ of 4% SDS solution was sprayed without using hair removal cream to break the skin barrier, followed by natural drying for 4 hours and then applying AD ointment. After applying AD Ointment ® three times a week for two weeks, sensory evaluation was carried out.
Modifide SCORAD score, which is a general clinical evaluation method for atopic dermatitis, was used as a sensory test. Four items (erythema / hemorrhage, edema, scaling, (dry), scored / excoriated / erosion] were scored as 0 (good), 1 (poor), 2 (poor), and 3 (very bad) Were selected and divided into four groups. The average score of each group was 10 points.
4-3. Evaluation of efficacy of guava butanol fraction
As a result, as shown in Fig. 4, the SCORAD score score of the fourth group in which a 1% guava butanol fraction was dissolved in glycerin was measured in a sensory evaluation after 7 days of application, and the SCORAD score score of the second group (SCORAD (SCORAD score, 5 points), which is the most common and effective treatment for atopic dermatitis, and 1% hydrocortisone ointment, The SCORAD score was significantly lower than that of the control group.
It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.
Claims (13)
The guava is a guava leaf ( Psidium guajava L.). ≪ / RTI >
Wherein the guava extract is obtained by extracting guava with water, an alcohol having 1 to 4 carbon atoms or a mixed solvent thereof.
Wherein the alcohol having 1 to 4 carbon atoms is methanol or ethanol.
Wherein the fraction is a hexane fraction, a dichloromethane fraction, an ethyl acetate fraction or a butanol fraction obtained by sequentially fractionating a guava extract with hexane, dichloromethane, ethyl acetate or butanol.
Wherein said composition inhibits melanogenesis through inhibition of the ORAI-I pathway.
Wherein the composition inhibits tyrosinase activity.
Wherein said composition inhibits skin blackening due to ultraviolet exposure.
Wherein the composition is a pharmaceutical composition.
Wherein the composition is a cosmetic composition.
Wherein the composition is a functional food composition.
Wherein the immunosuppression is through inhibition of the ORAI-I pathway.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140156059 | 2014-11-11 | ||
| KR1020140156059 | 2014-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160056268A true KR20160056268A (en) | 2016-05-19 |
Family
ID=56103390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150139525A KR20160056268A (en) | 2014-11-11 | 2015-10-05 | Composition for the inhibition of UV-induced melanogenesis or anti inflammatory comprising extracts or fractions of Psidium guajava L. |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160056268A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018056497A1 (en) * | 2016-09-26 | 2018-03-29 | 주식회사 프롬바이오 | Immunopotentiating food composition comprising amla fruit extract and guava leaf extract |
| KR101929500B1 (en) | 2018-07-27 | 2019-03-14 | 재단법인 전남생물산업진흥원 | Nano emulsion composition of guava and producing method thereof |
| WO2020013571A1 (en) * | 2018-07-09 | 2020-01-16 | 주식회사 레모넥스 | Pharmaceutical composition and functional health food for preventing or treating macular degeneration |
| CN114796319A (en) * | 2022-03-22 | 2022-07-29 | 山东第一医科大学(山东省医学科学院) | Preparation method and application of guava leaf extract |
| KR102472487B1 (en) | 2022-06-14 | 2022-12-01 | (주)올바름디앤비 | Cosmetic composition comprising natural extract mixture |
-
2015
- 2015-10-05 KR KR1020150139525A patent/KR20160056268A/en not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018056497A1 (en) * | 2016-09-26 | 2018-03-29 | 주식회사 프롬바이오 | Immunopotentiating food composition comprising amla fruit extract and guava leaf extract |
| WO2020013571A1 (en) * | 2018-07-09 | 2020-01-16 | 주식회사 레모넥스 | Pharmaceutical composition and functional health food for preventing or treating macular degeneration |
| US11633447B2 (en) | 2018-07-09 | 2023-04-25 | Lemonex Inc. | Pharmaceutical composition and functional health food for preventing or treating macular degeneration |
| KR101929500B1 (en) | 2018-07-27 | 2019-03-14 | 재단법인 전남생물산업진흥원 | Nano emulsion composition of guava and producing method thereof |
| CN114796319A (en) * | 2022-03-22 | 2022-07-29 | 山东第一医科大学(山东省医学科学院) | Preparation method and application of guava leaf extract |
| KR102472487B1 (en) | 2022-06-14 | 2022-12-01 | (주)올바름디앤비 | Cosmetic composition comprising natural extract mixture |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532560A (en) | Cosmetic composition containing extract of Dendrobium candidam flower | |
| KR102126470B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| CA2924382A1 (en) | Lipid extract of passion fruit seeds | |
| KR101800498B1 (en) | Composition for improving skin wrinkle comprising extract or compounds derived from unripe apple | |
| KR20160056268A (en) | Composition for the inhibition of UV-induced melanogenesis or anti inflammatory comprising extracts or fractions of Psidium guajava L. | |
| CN110072516B (en) | Cosmetic composition comprising extracts of Chinese medicinal materials as effective ingredients | |
| KR20160023310A (en) | Composition for anti-aging containing youngia denticulata extract | |
| EP3042651B1 (en) | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis | |
| KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
| KR101922089B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR20190018108A (en) | Composition Comprising Thymol for Preventing or Treating in Skin Wrinkle or Atopic Dermatitis as Active Ingredient | |
| KR101906896B1 (en) | Composition Comprising Thymol and Myrcene for Preventing or Treating in Atopic Dermatitis as Active Ingredient | |
| KR102105672B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR102120758B1 (en) | Composition for preventing, ameliorating or treating allergic disease comprising coffee extract as effective component | |
| KR102584473B1 (en) | Composition for improving skin conditions comprising Polygalaxanthone Ⅲ | |
| KR102503110B1 (en) | Composition for improving skin conditions comprising genipin-1-b-D-gentiobioside | |
| KR20180045346A (en) | Composition for the inhibition of UV-induced melanogenesis comprising extracts of Phellodendri Cortex, Anemarrhena asphodeloides, and Alismatis Rhizoma | |
| KR102605628B1 (en) | Composition for improving skin conditions comprising hastatoside | |
| KR102262362B1 (en) | Composition for improving skin conditions comprising an extract of oriental melon stem or cucumber stem | |
| KR101526435B1 (en) | Compositions for skin-whitening comprising extract of Vitis amurensis ruprecht | |
| KR102607716B1 (en) | A composition for preventing or improving circadian rhythm disorders comprising Artemisia annua plant extracts or artemisinin | |
| KR102264006B1 (en) | Composition for inhibiting production of melanin and promoting decomposition of melanin | |
| KR102104305B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising monomyristin or a pharmaceutically acceptable salt thereof | |
| KR102644107B1 (en) | Composition for skin improvement containing vomicine | |
| KR102145032B1 (en) | Cosmetic composition comprising mortierella oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |